FULGENT GENETIC (NASDAQ: FLGT) and Zeltiq Aesthetics (NASDAQ:ZLTQ) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Earnings & Valuation
This table compares FULGENT GENETIC and Zeltiq Aesthetics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|FULGENT GENETIC||$20.81 million||3.68||$2.17 million||($0.38)||-11.37|
FULGENT GENETIC has higher revenue and earnings than Zeltiq Aesthetics. FULGENT GENETIC is trading at a lower price-to-earnings ratio than Zeltiq Aesthetics, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings for FULGENT GENETIC and Zeltiq Aesthetics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
FULGENT GENETIC currently has a consensus price target of $10.67, indicating a potential upside of 146.91%. Zeltiq Aesthetics has a consensus price target of $56.83, indicating a potential upside of 0.63%. Given FULGENT GENETIC’s stronger consensus rating and higher probable upside, analysts clearly believe FULGENT GENETIC is more favorable than Zeltiq Aesthetics.
Institutional and Insider Ownership
16.8% of FULGENT GENETIC shares are owned by institutional investors. 15.6% of Zeltiq Aesthetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares FULGENT GENETIC and Zeltiq Aesthetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
About FULGENT GENETIC
Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc. is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system. CoolSculpting is a non-invasive fat reduction procedure. CoolSculpting utilizes its controlled cooling technology to selectively reduce stubborn fat bulges. The CoolSculpting system includes CoolSculpting control unit and CoolSculpting applicators. The CoolSculpting Applicator delivers vacuum suction and cooling to the fat bulge being treated.
Receive News & Ratings for FULGENT GENETIC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FULGENT GENETIC and related companies with MarketBeat.com's FREE daily email newsletter.